GENOTYPE POLYMORPHISMS OF NAT2 AND CYP2E1 GENES ASSOCIATED WITH DRUG INDUCED LIVER INJURY (DILI) IN INDONESIAN TUBERCULOSIS PATIENTS
Currently, Indonesia is in the fifth rank of highest TB prevalence over the world. One of the TB problem is low patients’ adherence due to the oral antituberculosis induced hepatotoxicity. Polymorphisms of NAT2 and CYP2E1 genes had important role in the isoniazid (INH)-induced hepatotoxicity. The aim of this study was to evaluate the polymorphisms profile of NAT2 and CYP2E1 genes associated with hepatotoxicity induced by INH.
We used cohort design in Public Health Centers and Lung Clinics of Yogyakarta and Lampung. The inclusion criteria were adult subjects (> 18 yo), newly diagnosed TB and treated by oral antituberculosis, normal function of renal and live and willingness to participate in this study. Subjects were excluded when having positive reaction of HbsAg test, history of HIV and abnormality of renal and liver function. The SNPs of NAT2 and CYP2E1 were designed using IPlex method of DNA sequenom.
Among 57 TB patients, we found 14 patients with higher INH serum concentration and experienced increase of ALT-AST. Subjects with SNPs of rs 2070676, rs 1329149, rs 3813867, rs 6413432, rs 8192772, rs 2031920, rs 2515641, rs 8192775, rs 915908 of CYP2E1 experienced increase of ALT and AST. Subjects with SNPs of rs 1799930, rs1799931, rs1801279, rs1801280, rs1799929 , rs1208, rs1041983 of NAT2 are associated with the increase of ALT and AST.
The polymorphisms of CYP2E1 and NAT2 may have a role in the mechanisms of INH induced DILI.
Keywords: CYP2E1, NAT2, tuberculosis, isoniazid, Indonesia
Anonymous, https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=ID&LAN=EN&outtype=html, it was accessed on 10 September 2015
An HR., Wu XQ., Wang ZY., Zhang JX., Liang Y. 2012. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 39(6):535-43.
Atthobari J., Mulyani UA., Perwitasari DA. 2013. Early Drug lnduced Liver lnjury After lntensive Phase of Tb Treatment in Indonesia: Primary Care Centers and Lung Hospital Study. Drug Safety . 36 (9),693
Babalık A., Arda H., Bakırcı N., Ağca S., Oruç K., Kızıltaş S., Cetintaş G., Calışır HC. 2012. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks. 60(2):136-44.
Chamorro JG., Castagnino JP., Musella RM., Nogueras M., Aranda FM., Frías A., Visca M., Aidar O., Perés S., de Larrañaga GF. 2013. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol. 28(2):323-8.
Costa, C.N.O., Luiz, A.V.M., Cinthia, V.N et al ., 2012, Genetic interaction between NAT2. GSTM1, GSTT1, CYP2E1, and environmental factor is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther. 16(4): 1-10
Gaude GS., Chaudhury A., Hattiholi J,. 2015. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care. 4(2):238-43.
Guaoua S., Ratbi I., Laarabi FZ., Elalaoui SC., Jaouad IC., Barkat A., Sefiani A. 2014. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genet. 29;15:156.
Gupta VH., Singh M., Amarapurkar DN., Sasi P., Joshi JM., Baijal R., H R PK., Amarapurkar AD., Joshi K., Wangikar PP. 2013. Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population. Ann Hepatol.12(6):959-65
Higuchi N., Tahara N., Yanagihara K., Fukushima K., Suyama N., InoueY., et al. 2007. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in japanese patients with tuberculosis, World Journal of Gastroenterology, 13(45): 6003-6008
Jeong I., Park JS., Cho YJ., Yoon HI., Song J., Lee CT., Lee JH. 2015. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 30(2):167-72.
Krishnakumar D., Umamaheswaran G., Kayathri et al. 2010. Genetic polymorphism of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in south indian population, Fundamental & Clinical Pharmacology, 26: 295-306
Lv X., Tang S., Xia Y., Zhang Y., Wu S., Yang Z., Li X., Tu D., Chen Y., Deng P., Ma Y., Chen D., Chen R., Zhan S.. 2012. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol. 11(5):700-7.
Mishra S., Daschakraborty S., Shukla P., Kapoor P., Aggarwal R. 2013. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population. Natl Med J India.26(5):260-5.
Nelwan., Stella P., Julia CML., 2014, Kadar serum glutamic oxaloacetat transminase dan serum glutamic pyruvic transminase pada pasien tuberkulosis paru selama dua bulan berjalannya pemberian obat anti tuberkulosis kombinasi dosis tetap, Jurnal E-Clinic, 2(3): 3-6
Perwitasari DA., Atthobari J., Wilffert B. 2015. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 47(2):222-8.
Rana S.V., Sharma S.K., Ola R.P., Kamboj J.K., Malik A., Morya R.K., Sinha SK. 2014. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians. J Clin Pharm Ther. 39(1):91-6.
Santos NP., Callegari-Jacques SM., Ribeiro Dos Santos AK., Silva CA., Vallinoto AC., Fernandes DC., de Carvalho DC., Santos SE., Hutz MH. 2013. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis. 17(4):499-504.
Sharma S., Cao X., Wilkens LR., Yamamoto J., Lum-Jones A., Henderson BE., et al. 2010. Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: The Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev. (7): 1866–1870.
Sheng Y.J., Wu G., He H.Y., Chen W., Zou Y.S., Li Q., Zhong L., Huang Y.M., Deng C.L.. 2014. The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis. Infect Genet Evol. 24:34-40.
Tang, S., Xiaozhen, L., Yuan, Z et al., 2013, Cytochrome p450 2E1 gene polymorphism/haplotypes and anti-tuberculosis drug-induced hepatitis in a chinese cohort. PlosOne 8(2): e57526
Tesfahuneygn G., Medhin G., Legesse M. 2015. Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes. 8: 503.
Xiang Y., Ma L., Wu W., Liu W., Li Y., Zhu X., et al. 2014. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One. 23;9(1):e85905.
Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F.Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009 Sep;10(9):1433-45..
Yang, H., Zhou, Y., Liu et al . 2009. A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism rs671 of ALDH2 of alcohol metabolizing enzymes are associated with colorectal cancer in a southwestern shinese population, Cancer Epidemiol Biomarkers. 18(9): 2522-7.2009
- There are currently no refbacks.
Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Indonesian J Pharm indexed by:View My Stats